Table 1 Overview of the brain samples analyzed in this study.
From: Differential microRNA expression analyses across two brain regions in Alzheimer’s disease
STG | EC | |||
|---|---|---|---|---|
AD cases | AD controls | AD cases | AD controls | |
Total number | 99 | 91 | 90 | 84 |
Sex | ||||
Male/female ratio | 50/49 | 51/40 | 46/44 | 44/40 |
p-value1 | 0.5360 | 0.9875 | ||
Age at death (years) | ||||
Average (±SD) | 81.59 (8.03) | 77.48 (13.76) | 82.04 (7.76) | 77.70 (13.93) |
Median (IQR) | 83.00 (77.5-87.00) | 81.00 (68.50–88.50) | 83.00 (78.00–87.75) | 81.00 (68.75–89.00) |
Range | 61-95 | 41-100 | 61-95 | 41-100 |
p-value2 | 0.0142 | 0.0131 | ||
PMI (h) | ||||
Average (±SD) | 57.07 (30.56) | 48.41 (30.95) | 56.43 (30.56) | 49.01 (32.07) |
Median (IQR) | 48 (30–73.75) | 48 (24–48) | 48.00 (30–72) | 48.00 (24–52) |
Range | 9–140 | 5–168 | 9–140 | 5–168 |
p-value2 | 0.0540 | 0.1209 | ||
RIN value | ||||
Average (±SD) | 3.03 (1.21) | 4.19 (1.39) | 2.89 (1.05) | 3.05 (1.17) |
Median (IQR) | 2.60 (2.30–3.25) | 4.00 (2.95–5.20) | 2.65 (2.025–3.775) | 3.050 (2.1–3.8) |
Range | 1.20–7.80 | 2.10–7.60 | 1.3–6.0 | 1.2–6.3 |
p-value2 | <0.001 | 0.3513 | ||
RNA A260/280 | ||||
Average (±SD) | 1.90 (0.04) | 1.93 (0.04) | 1.94 (0.03) | 1.95 (0.04) |
Median (IQR) | 1.89 (1.86–1.94) | 1.93 (1.91–1.95) | 1.94 (1.91–1.96) | 1.95 (1.94–1.96) |
Range | 1.80–1.99 | 1.80–2.00 | 1.84–2.01 | 1.77–2.06 |
p-value2 | <0.001 | 0.0068 | ||
Braak Stage | ||||
Stage 0 | 0 | 6 | 0 | 5 |
Stage I/II | 0 | 72 | 0 | 66 |
Stage III | 0 | 6 | 0 | 6 |
Stage IV | 8 | 0 | 8 | 0 |
Stage V/VI | 91 | 0 | 82 | 0 |
n.a. | 0 | 7 | 0 | 7 |
